Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

9.8K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.8K
Antibiotic Selection00:57

Antibiotic Selection

60.0K
Overview
60.0K
What is Natural Selection?01:32

What is Natural Selection?

129.5K
Natural selection is an evolutionary process in which individuals with survival-promoting traits reproduce at higher rates. These favorable traits become more common within a population or species. Naturally selected traits initially arise via random genetic mutations. In order for selection to occur, there must be variation within a population, the trait controlling the variation must be heritable, and there must be an evolutionary advantage for variation in the trait.
129.5K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

362
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
362
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

305
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
305
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

244
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
244

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retaining Versus Engaging Youth in HIV Care: Perspectives From a Qualitative Study among Youth Living With HIV and Their Care Providers in Kenya and Uganda.

Journal of the International Association of Providers of AIDS Care·2026
Same author

El Niño events recorded by redox sensitive trace elements in sedimentary records from Genovesa Lake, Galápagos.

The Science of the total environment·2026
Same author

Effect of Biomarker Confirmed Unhealthy Alcohol Use on Viral Suppression Among Adolescents and Young Adults With HIV in East Africa.

Journal of the International Association of Providers of AIDS Care·2026
Same author

Youths' strategies for HIV status disclosure in rural Kenya and Uganda: You can't just trust everyone".

SSM. Qualitative research in health·2026
Same author

Effects of mindfulness training on sustained attention and mind-wandering in older adults: results from the HealthyAgers randomized controlled trial.

The journals of gerontology. Series B, Psychological sciences and social sciences·2025
Same author

Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.

EBioMedicine·2025

Related Experiment Video

Updated: Feb 5, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K

Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance.

Hardik Chandasana1, Ann M Buchanan2, Cassidy A Henegar3

  • 1From the Clinical Pharmacology Modeling Simulation, GSK, Collegeville, PA.

The Pediatric Infectious Disease Journal
|February 4, 2026
PubMed
Summary

A new weight-tiered, twice-daily Dolutegravir dose is proposed for children with HIV. This dosing aims to achieve therapeutic Dolutegravir exposures, ensuring similar efficacy and safety as observed in adults.

Keywords:
HIV-1INSTI resistancedolutegravirexposure–responsepediatrics

More Related Videos

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Related Experiment Videos

Last Updated: Feb 5, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.0K
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.4K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Pediatrics

Background:

  • Dolutegravir is an integrase strand transfer inhibitor used for HIV treatment.
  • Current dosing is approved for adults but not for pediatric populations.
  • HIV-1 resistance to integrase strand transfer inhibitors is a growing concern.

Purpose of the Study:

  • To establish a weight-tiered, twice-daily Dolutegravir dosing regimen for children.
  • To predict Dolutegravir exposures in pediatric patients using population pharmacokinetic modeling.
  • To evaluate the potential for similar efficacy and safety in children compared to adults.

Main Methods:

  • Population pharmacokinetic modeling was employed.
  • Simulations were conducted to assess dosing outcomes.
  • Weight-tiered dosing strategies were analyzed.

Main Results:

  • A weight-tiered, twice-daily Dolutegravir dose was identified for pediatric use.
  • Simulations predicted Dolutegravir exposures within the therapeutic window.
  • The proposed dosing is expected to provide efficacy and safety comparable to adults.

Conclusions:

  • The identified weight-tiered dosing regimen offers a potential solution for pediatric Dolutegravir treatment.
  • Pharmacokinetic modeling supports the use of this regimen in children with HIV.
  • Further clinical validation is warranted to confirm efficacy and safety in pediatric populations.